Integrin β8 facilitates tumor growth and drug resistance through a Y‐box binding protein 1‐dependent signaling pathway in bladder cancer. Issue 7 (25th May 2020)

• Record Type: Journal Article
• Authors: Liu, Shimin; Chen, Libo; Zhao, Heng; Li, Qin; Hu, Rong; Wang, Hao
• Is Part Of: Cancer science. Volume 111:Issue 7(2020)
• Page Start: 2423
• Page End: 2430
• Publication Date: 2020-05-25
• Subjects: bladder cancer -- c‐Myc -- integrin β8 -- NF‐κB -- YBX1; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14439
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: The transmembrane receptors integrins are the bridges for cell‐cell or cell‐ECM interaction, which is strictly correlated to cancer development in several tumor types. Here, we revealed that integrin β8 serves as a driver to mediate sustained growth of bladder cancer and development of drug resistance. The elevated expression of integrin β8 was observed in highly malignant bladder tumor tissues from patients. The in vitro and in vivo results further indicated that integrin β8 overexpression in Biu87/T24 bladder cancer could mediate and strengthen cell proliferation and resistance to mitomycin C and hydroxycamptothecin. Mechanistically, integrin β8 on the cellular surface might recruit phosphorylated Y‐box binding protein 1, leading to the activation of c‐Myc and nuclear factor‐κB signals. Pharmacological targeting of integrin β8 by Arg‐Gly‐Asp‐Ser efficiently suppressed sustained growth and drug resistance in bladder cancer cells. Our findings identified integrin β8 as a marker of bladder cancer diagnosis and development, and provides an innovative approach for clinical bladder cancer therapy. Abstract : We found that integrin β8 expression induces bladder cancer sustained growth and drug resistance through a Y‐box binding protein 1‐associated signaling pathway. Blockade of integrin β8 efficiently improves anticancer effects, revealing a new target for bladder cancer therapy.